COIOSDeep risk insights through multi-disciplinary research across the globe
Layered rock face with brown and grey textures
Item refines Preprint · not peer-reviewed Added

Brain-derived plasma p-tau217% outperforms standard p-tau217 for Alzheimer's pathology

Brain-derived plasma p-tau217% separated low from severe Alzheimer's neuropathological change with an AUC of 0.93, against 0.90 for standard p-tau217.

BD-p-tau217% is the proportion of brain-derived plasma tau phosphorylated at threonine 217. It was tested in autopsy (323), PET (242) and clinical (1,386) cohorts from one Pittsburgh memory clinic. It separated low from severe neuropathological change with an AUC of 0.93, against 0.90 for standard p-tau217. For amyloid PET it had 92% sensitivity and 88% specificity, against 79% and 82% for p-tau217. High levels predicted clinical progression, with hazard ratios of 3.21 in clinically unimpaired people and 3.65 in mild cognitive impairment. Limits include a single centre, a 91.5% non-Hispanic White clinical cohort, and no significant AUC gain for unimpaired progressors.

Why it is interesting: Standard p-tau217 partly comes from tissues outside the brain, which may cloud blood-based diagnosis in older people with other illnesses. Here accuracy stayed at AUC 0.84 to 0.88 among those with comorbidities.

Source
medRxiv, 8 November 2026
Paper
CNS-selective plasma p-tau217 accurately captures Alzheimer’s disease pathology and progression
Authors
Zeng X, Farinas MF, Nafash MN, Smirnov DS, Shi R, Lopresti BJ et al.
DOI
10.64898/2026.05.18.26353208
Full text
Open copy (open-access copy, PubMed Central)
Type
Preprint
Design
Multi-cohort biomarker validation (neuropathologically defined, amyloid/tau PET-characterised and memory clinic cohorts; follow-up up to 20 years; n not stated)
Verdict
Refines prior evidence
Driver
Dementia

Other drivers in Health today